CORDIS
EU research results

CORDIS

English EN

DEVELOPMENT OF NEW GYRASE INHIBITORS BY COMBINATORIAL BIOSYNTHESIS

Objective

The aim of this project is to generate novel inhibitors of gyrase and topoisomerase IV by engineering the biosynthetic pathways of very potent natural inhibitors of these enzymes. The project will focus on antibiotics of the aminocoumarin type (novobiocin, clorobiocin, coumermycin A1, simocyclinones) and the cyclothialidine type (cyclothialidine and GR12222X). All these compounds are produced by Stneptomyces strains. The interaction of novobiocin, clorobiocin and the cyclothialidines with bacterial gyrase has been elucidated with biophysical and X-ray crystallographic techniques by members of this consortium. The interaction of the simocyclinones, and of newly generated inhibitors, with gyrase and topoisomerase IV will be investigated in this project. The results will be utilized for rational approaches for the development of new inhibitors by genetic engineering. The complete gene clusters involved in the biosynthesis of novobiocin, clorobiocin, coumermycin and simocyclinone have been cloned and sequenced by the members of this consortium. The biosynthetic gene cluster of cyclothialidine will be identified in this project. Genes and operons within the gene clusters will be modified by gene inactivation, gene expression or gene replacement experiments within the natural producers. Furthermore, vectors containing entire biosynthetic gene clusters will be modified in E. coli and subsequently introduced into suitable Streptomyces host strains for production of novel metabolites. New molecules will also be generated by feeding specific strains with synthetic analogues of precursors of biosynthesis. Accumulated compounds will be modified chemically in order to generate an even wider array of new molecules. The biological activity of the novel molecules will be assayed using enzyme assay systems with gyrase and topoisomerase IV and antibacterial assays with human pathogens. Promising drug candidates will be investigated in animal infection models...

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

EBERHARD KARLS-UNIVERSITAET TUEBINGEN

Address

Wilhelmstrasse 7
Tuebingen

Germany

Participants (6)

Sort alphabetically

Expand all

UNIVERSIDAD DE OVIEDO

Spain

ALBERT-LUDWIGS-UNIVERSITAET FREIBURG

Germany

JOHN INNES CENTRE

United Kingdom

UNIVERSITA DEGLI STUDI DI PADOVA

Italy

COMBINATURE BIOPHARM AG

Germany

BASILEA PHARMACEUTICA LTD

Switzerland

Project information

Grant agreement ID: 503466

  • Start date

    1 January 2004

  • End date

    31 December 2006

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 2 170 690

  • EU contribution

    € 1 555 415

Coordinated by:

EBERHARD KARLS-UNIVERSITAET TUEBINGEN

Germany